- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01266759
Efficacy of Combined Contraceptive Vaginal Ring(NuvaRing)in Women With Idiopathic Menorrhagia
December 23, 2010 updated by: Mansoura University
Combined Contraceptive Vaginal Ring or Norethisterone for Treatment of Idiopathic Menorrhagia
To compare the efficacy of a combined contraceptive vaginal ring (NuvaRing) and oral Norethisterone Acetate in treatment of Idiopathic heavy menstrual bleeding during fertile age
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
95
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Dakahlia Governorate
-
Mansoura, Dakahlia Governorate, Egypt
- Mansoura University Hospitals,OB/GYN department
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 33 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Women with heavy menstrual bleeding based on PBAC score over 185 (mean of two control cycles)and desire contraception
Exclusion Criteria:
- Menorrhagia of endocrine or systemic origin
- other pathology e.g. patients with fibroids of any size, adenomyosis, endometriosis, pelvic inflammatory disease.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: NuvaRing
For the first cycle, women inserted the ring between days 1 and 5 of the menstrual cycle.
Treatment continued for three cycles.
Each cycle consisted of 3 weeks of ring use followed by a 1 week ring-free period.
|
For the first cycle, women inserted the ring between days 1 and 5 of the menstrual cycle.
Treatment continued for three cycles.
Each cycle consisted of 3 weeks of ring use followed by a 1 week ring-free period.
|
Active Comparator: Norethisterone Acetate
Norethisterone Acetate tablets at a dose of 5 mg three times daily from day 5 to 26 of the cycle over three cycles.
Male condom used for contraception during treatment
|
Norethisterone Acetate tablets 5 mg three times daily from day 5 to 26 of the cycle over three cycles.
Male condom used for contraception during treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Reduction in menstrual blood loss at the end of study (cycle 3) measured by pictorial blood loss assessment chart.
|
Secondary Outcome Measures
Outcome Measure |
---|
Haemoglobin and serum ferritin at the end of study (cycle 3)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Waleed El-Sherbini, MD, Mansoura University Hospital
- Study Chair: Mohamed Bazeed, MD, Mansoura University Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Matteson KA, Boardman LA, Munro MG, Clark MA. Abnormal uterine bleeding: a review of patient-based outcome measures. Fertil Steril. 2009 Jul;92(1):205-16. doi: 10.1016/j.fertnstert.2008.04.023. Epub 2008 Jul 16.
- Oddsson K, Leifels-Fischer B, Wiel-Masson D, de Melo NR, Benedetto C, Verhoeven CH, Dieben TO. Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 microg ethinylestradiol and 150 microg levonorgestrel: a randomized trial. Hum Reprod. 2005 Feb;20(2):557-62. doi: 10.1093/humrep/deh604. Epub 2004 Nov 11.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2008
Primary Completion (Actual)
September 1, 2010
Study Completion (Actual)
September 1, 2010
Study Registration Dates
First Submitted
December 22, 2010
First Submitted That Met QC Criteria
December 23, 2010
First Posted (Estimate)
December 24, 2010
Study Record Updates
Last Update Posted (Estimate)
December 24, 2010
Last Update Submitted That Met QC Criteria
December 23, 2010
Last Verified
December 1, 2010
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Uterine Diseases
- Hemorrhage
- Menstruation Disturbances
- Uterine Hemorrhage
- Menorrhagia
- Physiological Effects of Drugs
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptives, Oral
- Contraceptive Agents, Female
- Contraceptives, Oral, Synthetic
- Contraceptives, Oral, Hormonal
- Norethindrone
- Norethindrone Acetate
- NuvaRing
Other Study ID Numbers
- MU-261z
- FMH-245-C
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Menorrhagia
-
BayerCompletedIdiopathic MenorrhagiaCroatia, South Africa, Colombia, Czech Republic, Jordan, Lebanon, Macedonia, The Former Yugoslav Republic of, Moldova, Republic of, Romania, Ukraine, Venezuela, Bosnia and Herzegovina, Syrian Arab Republic, Albania
-
Minerva Surgical, Inc.CompletedMenorrhagia Due to Benign CausesHungary
-
Minerva Surgical, Inc.CompletedMenorrhagia Due to Benign CausesMexico
-
Minerva Surgical, Inc.CompletedMenorrhagia Due to Benign CausesCanada
-
BayerCompletedIdiopathic MenorrhagiaCroatia, Saudi Arabia, Bulgaria, Jordan, Romania, Russian Federation, Turkey, United Arab Emirates, Kuwait, India, Pakistan, Serbia, Sri Lanka
-
Legacy Health SystemUnknownMenopause | Climacteric; Menorrhagia, MenopausalUnited States
-
University of Sao PauloRecruitingCardiovascular Diseases | Arterial Hypertension | Postmenopausal; MenorrhagiaBrazil
-
BayerCompletedMenorrhagia, DysmenorrheaJapan
-
Faculty of Medicine, SousseCentre Hôpital Universitaire Farhat HachedCompletedMetrorrhagia | Hysterectomy | Heavy Menstrual Bleeding | Abnormal Uterine Bleeding | Menorrhagia; PostmenopausalTunisia
-
University of Sao PauloRecruitingMotor Activity | Physical Inactivity | Postmenopausal; MenorrhagiaBrazil
Clinical Trials on NuvaRing
-
Evestra Inc.RecruitingContraception | Female | Healthy WomenCanada
-
Centers for Disease Control and PreventionKenya Medical Research InstituteCompleted
-
University Hospital, GhentFund for Scientific Research, Flanders, BelgiumCompleted
-
University of WashingtonNational Institute of Allergy and Infectious Diseases (NIAID)CompletedBacterial VaginosisUnited States
-
Organon and CoCompletedContraception: Optional Applicator for Insertion of Vaginal Ring
-
Desmond Tutu HIV CentreUnknown
-
University of WashingtonEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedHIV | Bacterial VaginosisKenya
-
Organon and CoCompleted
-
Oregon Health and Science UniversityOregon Clinical and Translational Research InstituteCompletedContraceptive Usage | Vaginal Epithelial DisruptionUnited States
-
Eastern Virginia Medical SchoolMerck Sharp & Dohme LLCUnknownVaginosis, BacterialUnited States